Erdheim-Chester Disease

This is a very rare disease. It affects the body's immune system, causing cells to grow abnormally. This leads to inflammation and scarring in different parts of the body, especially in the bones. It usually starts in middle age.

Condition

What people with Erdheim-Chester Disease report

Every report comes from a Lived member, sent anonymously.

Have you tried Zelboraf (Vemurafenib) for Erdheim-Chester Disease?

NameHow it went

About Erdheim-Chester Disease

What It Is

Erdheim-Chester disease (ECD) is a rare, usually slow-growing blood cancer. It belongs to a group called histiocytic neoplasms, in which the body makes too many histiocytes, immune cells that normally clean up debris and help fight infection. In ECD these cells build up in tissues and organs, causing inflammation that can leave them thickened and scarred. Over time, that scarring can interfere with how an organ works. Because the cells can settle almost anywhere, ECD looks different from person to person. The most common feature is hardening of the long bones of the legs, which often causes aching in both knees and lower legs. Other typical sites include the pituitary gland at the base of the brain, where damage can cause diabetes insipidus (a shortage of the hormone that helps the kidneys hold on to water, leading to heavy urination and constant thirst), the tissue around the kidneys, the heart and the large blood vessels. Some people develop bulging eyes, yellowish patches on the eyelids, breathing problems or difficulties with balance and speech. Fever, night sweats, tiredness and weight loss can also occur. ECD most often begins between ages 40 and 60 and is slightly more common in men. Its severity ranges widely: some people have few health problems, while others have serious involvement of the heart, lungs, kidneys or brain. ECD is distinct from Langerhans cell histiocytosis, a related condition that more often affects children and produces different bone changes.

Causes & Risk Factors

ECD is caused by a genetic change that develops during a person's lifetime in histiocytes or the bone marrow cells that give rise to them. This kind of change is called somatic: it is not present from birth, it is not inherited and it cannot be passed to children. The altered gene keeps a cell-growth signaling pathway (the MAPK pathway) switched on, so the cells keep multiplying and driving inflammation. More than half of people with ECD have one specific change, called BRAF V600E, in the BRAF gene. Others have changes in related genes in the same pathway. Which change a person has matters mainly because it helps decide treatment. No lifestyle factor, infection or exposure is known to cause ECD, and nothing a person did is known to have brought it on.

How It's Diagnosed

ECD is often diagnosed late. Its symptoms develop gradually, appear in organs that seem unrelated and can resemble more common inflammatory diseases or cancers, so people may see several specialists before the pieces are put together. Imaging usually provides the first strong clue. X-rays or bone scans often show symmetrical hardening in the shafts of the leg bones, with the joint ends spared, a pattern that is highly suggestive of ECD. CT and MRI scans look at organs such as the kidneys, heart, blood vessels and brain. A PET-CT scan, which uses a small amount of radioactive sugar to highlight active disease, can map where ECD is present throughout the body and is later used to judge whether treatment is working. The diagnosis is confirmed with a biopsy, a tissue sample taken from an affected area such as bone or the tissue around the kidneys. Under the microscope, ECD shows fat-filled, foamy-looking histiocytes with surrounding inflammation and scarring. The biopsy is also tested for BRAF and other gene changes, because the result guides the choice of treatment. Because ECD can affect many organs silently, the initial assessment usually also checks heart, kidney and hormone function.

Treatment Options

There is no cure for ECD, but treatment can often control it for long periods. Most people with ECD need treatment. A small number with mild disease limited to one organ, and few symptoms, may be monitored instead. Care is ideally guided by a team with experience in histiocytic disorders. Targeted drugs that block the overactive MAPK pathway are now the main treatment. Vemurafenib (Zelboraf), a BRAF inhibitor taken as tablets, is approved by the US Food and Drug Administration (FDA) for ECD with a BRAF V600 change. In the study that supported its approval, about half of 22 people had measurable shrinkage of their disease, and responses typically took months to appear. MEK inhibitors act one step further along the same pathway, so they can work whether or not a BRAF change is present. Cobimetinib (Cotellic) is FDA-approved for adults with histiocytic neoplasms, including ECD. In a 2026 study of 159 people treated with MEK inhibitors, about 7 in 10 improved and most of the rest stayed stable, with the best response often taking a year or more. These medicines have real trade-offs. Side effects are common, and in the MEK inhibitor study about 1 in 4 people had a severe one; side effects were the main reason people stopped. Vemurafenib makes the skin very sensitive to sun and can cause new skin cancers, so regular skin checks are part of treatment. Cobimetinib requires regular eye checks and monitoring of heart function. Doses are often lowered to make treatment more tolerable while keeping the disease controlled. Treatment is usually long-term. When a BRAF inhibitor is stopped for good after a good response, the disease comes back in up to three quarters of people. Lower doses and planned short breaks from treatment are being studied as ways to reduce side effects while keeping control. Older treatments, including pegylated interferon-alpha (an injected immune-modifying drug) and chemotherapy, remain options when targeted drugs are unsuitable or unavailable, although targeted drugs produce higher response rates. Radiation is not effective for ECD, and surgery has a limited role. Clinical trials are an important route to newer options.

What to Expect

ECD is a long-term condition that usually progresses slowly, but its course varies a great deal. Historically the outlook was poor, particularly with heart, lung or brain involvement. Targeted treatments have substantially improved outcomes, and many people now live for years with their disease controlled. Improvement is gradual. Bone pain, energy and other symptoms may take many months to respond, and follow-up PET-CT scans, blood tests and organ checks track whether the disease is quieting down. Damage that has already happened, such as pituitary hormone loss or scarring, may not fully reverse, so some people need ongoing treatment for those effects even when ECD itself is controlled. Brain involvement deserves particular mention. In roughly 15 to 20 percent of people, ECD gradually affects parts of the brain that control balance, coordination and speech. This form tends to respond less well to treatment, so finding it early matters. Daily life often revolves around managing a long-term medicine: regular appointments, sun protection, skin and eye checks and working with the care team to balance side effects against disease control. Because ECD is so rare, many people travel to a specialist center for some of their care while their local doctors handle routine follow-up.

When to Seek Help

Arrange a medical evaluation if you have persistent aching in both legs or knees together with unexplained symptoms elsewhere, such as heavy urination and constant thirst, bulging eyes or yellowish patches on the eyelids, especially if no cause has been found. If you have ECD, contact your care team promptly about new unsteadiness, clumsiness or slurred speech, increasing breathlessness, or a noticeable drop in how much you urinate. While taking a targeted drug, also report new or changing skin growths, vision changes or side effects that make it hard to keep taking the medicine, rather than stopping it on your own.

Questions to Ask Your Doctor

  1. 1.Which organs does my ECD involve, and which of them need the closest monitoring?
  2. 2.What did genetic testing of my biopsy show, and how does that affect my treatment choices?
  3. 3.What benefits and side effects should I expect from the treatment you recommend, and how will we judge whether it is working?
  4. 4.How long am I likely to need treatment, and what happens if side effects become hard to tolerate?
  5. 5.Should I be seen at a center with experience in histiocytic disorders, or consider a clinical trial?

Last reviewed • Oct 2026

Educational content, not medical advice.